Pulmonale Hypertonie bei Lungen- und Linksherzerkrankungen

详细信息    查看全文

• 作者：Dr. M. Held ; S. Rosenkranz
• 关键词：Lungenerkrankungen ; Herzerkrankungen ; Komorbidit盲ten ; Schlafapnoesyndrom ; Behandlung ; Pulmonary diseases ; Heart diseases ; Comorbidities ; Sleep apnea syndrome ; Treatment
• 刊名：Der Pneumologe
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：12
• 期：5
• 页码：410-416
• 全文大小：355 KB
• 参考文献：1.Adamson PB, Abraham WT, Bourge RC et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7:935鈥?44CrossRef PubMed
  2.Badesch DB, Raskob GE, Elliott CG et al (2010) Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137:376鈥?87CrossRef PubMed
  3.Blanco I, Gimeno E, Munoz PA et al (2010) Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 181:270鈥?78CrossRef PubMed
  4.Bonderman D, Ghio S, Felix SB et al (2014) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502鈥?11CrossRef
  5.Bradley TD, Rutherford R, Grossmann RF et al (1985) Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 131:835鈥?39PubMed
  6.Bursi F, McNallan SM, Redfield MM et al (2012) Pulmonary pressures and death in heart failure. J Am Coll Cardiol 59:222鈥?31PubMed Central CrossRef PubMed
  7.Bursi F, Barbieri A, Grigioni F et al (2010) Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a long-term outcome study. Eur J Heart Fail 12:382鈥?88CrossRef PubMed
  8.D鈥橝lto M, Romeo E, Argiento P et al (2015) Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. J Am Soc Echocardiogr 28:108鈥?15CrossRef
  9.Dumitrescu D, Seck C, M枚hle L et al (2012) Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension 鈥?results of compassionate care treatment. Int J Cardiol 154:205鈥?06CrossRef PubMed
  10.Fletcher EC, Schaaf JM, Miller J et al (1987) Long-term cardiopulmonary sequelae in patients with sleep apnea and chronic lung disease. Am Rev Respir Dis 135:525鈥?33PubMed
  11.Gali猫 N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493鈥?537CrossRef PubMed
  12.Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126鈥?32CrossRef PubMed
  13.Gerges C, Gerges M, Lang MB et al (2013) Diastolic pulmonary vascular pressure gradient. A predictor of prognosis in out-of-proportion pulmonary hypertension. Chest 143:758鈥?66CrossRef PubMed
  14.Ghio S, Gavazzi A, Campana C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183鈥?88CrossRef PubMed
  15.Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164鈥?74CrossRef PubMed
  16.Hawrylkiewicz I, Sliwinski P, Gorecka D et al (2004) Pulmonary haemodynamics in patients with OSAS or an overlap syndrome. Monaldi Arch Chest Dis 61:148鈥?52PubMed
  17.Held M, Jany B (2013) Pulmonary Hypertension in COPD. Respir Care 58(8):e86鈥揺91CrossRef PubMed
  18.Held M, Meintz S, Baron S et al (2013) Surgical cure of central sleep apnea? Am J Respir Crit Care Med 188:395鈥?96CrossRef PubMed
  19.Held M, Walthelm J, Baron S et al (2014) Functional impact of pulmonary hypertension due to hypoventilation and changes under NIPPV. Eur Respir J 43:156鈥?65CrossRef PubMed
  20.Hoeper MM, Huscher D, Ghofrani AH et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:871鈥?80CrossRef PubMed
  21.https://www.clinicaltrials.gov/ct2/results?term=RISE+IIP&Search=Search. Zugegriffen: 13. Apr. 2015
  22.Kusunose K, Popovi膰 ZB, Motoki H, Marwick TH (2013) Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging 6:167鈥?76CrossRef PubMed
  23.Lam CS, Roger VL, Rodeheffer RJ et al (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119鈥?126PubMed Central CrossRef PubMed
  24.Lancellotti P, Magne J, Dulgheru R et al (2015) Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol 115:1454鈥?461CrossRef PubMed
  25.Leuchte HH, Baumgartner RA, Nounou ME et al (2006) Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 173:744鈥?50CrossRef PubMed
  26.Melenovsky V, Hwang SJ, Lin G et al (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 35:3452鈥?462CrossRef PubMed
  27.Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC Heart Fail 1:290鈥?99CrossRef PubMed
  28.Nathan SD, Shlobin OA, Ahmad S et al (2008) Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 76:288鈥?94CrossRef PubMed
  29.Oswald-Mammoser M, Weitzenblum E et al (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 107:1193鈥?198CrossRef
  30.Patel NM, Lederer DJ, Borczuk AC et al (2007) Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132:998鈥?006CrossRef PubMed
  31.Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268鈥?277CrossRef PubMed
  32.Rosenkranz S, Bondermann D, Buerke M et al (2011) Pulmonary hypertension due to left heart disease: updated recommendations of the Cologne consensus conference 2011. Int J Cardiol 154(Suppl):S34鈥揝44CrossRef PubMed
  33.Scharf SM, Iqbal M, Keller C et al (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166:314鈥?22CrossRef PubMed
  34.Schulz R, Baseler G, Ghofrani HA et al (2002) Nocturnal periodic breathing in primary pulmonary hypertension. Eur Respir J 19:658鈥?63CrossRef PubMed
  35.Schulz R, Fegbeutel C, Olschewski H (2004) Reversal of nocturnal periodic breathing in pulmonary hypertension after lung transplantation. Chest 125:334鈥?47CrossRef
  36.Seeger W, Adir Y, Barber脿 JA et al (2013) Pulmonary hypertension in chronic lung diseases 2013. J Am Coll Cardiol 62(25 Suppl):D109鈥揇116CrossRef PubMed
  37.Shorr AF, Wainright JL, Cors CS et al (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30:n715鈥搉721CrossRef
  38.Seimetz M, Parajuli N, Pichl A (2011) Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 147:293鈥?05CrossRef PubMed
  39.Stolz H, Rasch A, Linka A (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32:619鈥?28CrossRef PubMed
  40.Tampakakis E, Leary PJ, Selby VN et al (2015) The diagnostic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail 3:9鈥?6CrossRef PubMed
  41.Thabut G, Dauriat G, Stern JB et al (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127:1531鈥?536CrossRef PubMed
  42.Vachiery JL, Adir Y, Barbera JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(Suppl D):D100鈥揇108CrossRef PubMed
  43.Wells JM, Washko GR, Han MLK et al (2012) Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 367:913鈥?21PubMed Central CrossRef PubMed
  44.Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81鈥?8CrossRef PubMed
  
• 作者单位：Dr. M. Held (1)
  S. Rosenkranz (2)
  
  1. Zentrum f眉r Pulmonale Hypertonie und Lungengef盲脽krankheiten, Abteilung Innere Medizin, Pneumologie und Kardiologie, Missions盲rztliche Klinik, Salvatorstr. 7, 97074, W眉rzburg, Deutschland
  2. Klinik III f眉r Innere Medizin, Herzzentrum der Universit盲t zu K枚ln und Cologne Cardiovascular Research Center (CCRC), K枚ln, Deutschland
  
• 刊物主题：Pneumology/Respiratory System; Medicine/Public Health, general; Allergology; Internal Medicine; Infectious Diseases; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1613-6055

文摘

Increasing awareness of pulmonary hypertension (PH) leads to an increased detection rate even in elderly patients with a higher rate of comorbidities. In patients with PH and left-sided heart or pulmonary diseases it is necessary to assess if these cardiac or pulmonary conditions are the cause of PH or only independent comorbidities. Additionally, it has to be evaluated if a chronic left-sided ventricular disease with pulmonary congestion has induced a pulmonary vasculopathy with severe PH. Sleep apnea syndrome can underlie PH and severe PH can lead to central sleep apnea. These aspects require experience and a careful and extensive diagnostic evaluation, including complete hemodynamic assessment, imaging techniques, lung function and cardiopulmonary exercise testing. Experienced PH centers should be involved in this diagnostic process at an early stage. Although PH leads to a worsening of the prognosis of pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) as well as of diastolic and systolic heart failure, published data do not support targeted PH therapies under these conditions due to a lack of evidence. Therefore, the treatment of the underlying disease is the primary goal. Mitral valve repair and non-invasive pressure ventilation in patients with alveolar hypoventilation lead to hemodynamic and functional improvement. Patients with PH and left heart disease show improvement following normalization of volume load. So far there are no approved medical therapies for PH due to left-sided heart disease and PH due to lung diseases. Patients with PH and left-sided heart diseases and lung diseases should be introduced in specific clinical studies. Keywords Pulmonary diseases Heart diseases Comorbidities Sleep apnea syndrome Treatment